Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beecham phenol/dyclonine OTC feedback meeting

Executive Summary

On Dec. 6, the firm presented a protocol it will submit in support of a long-lasting relief claim for throat and mouth soreness, according to FDA. The protocol involves a "new method" for determining the effectiveness of the anesthetic combo, that involves a programmable device to direct streams of air to the back of the throat. The combination's effect on modifying the stimulus is then measured. The agency requested that Beecham submit results of a comparison of the new method v. the "old method" of applying electric currents to the tongue. The active ingredient of Sucrets is dyclonine hydrochloride....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel